Having trouble viewing this email? View in your browser.

13 March 2018

Dear colleagues,

ECCMID from 21 – 24 April 2018 in Madrid has just received 28 European CME credits from the European Accreditation Council for Continuing Medical Education (EACCME), 5 credits more than in previous years.

Simone Brüderli in March joined the team at the society's Executive Office in Basel as Office Manager. Simone previously worked at DHL Express as Head of Business Relations.

You still have until 18 March to submit your application for the funded ESCMID observership programme. Please ensure that you tick the “funded” box, unless you are not looking for any financial support, in which case you can apply for an unfunded visit throughout the year. Please also ensure that you submit your final application before 18 March.

As a presenter of a paper poster you have the option to print out your posters onsite if you don’t want to carry the poster with you.

Your ESCMID communications editors


ESCMID-ECMM-ERS guideline on diagnosis and treatment of Aspergillus published

ESCMID jointly with the European Confederation of Medical Mycology and the European Respiratory Society has published a guideline on the diagnosis and management of aspergillosis.

The experts strongly recommend chest computed tomography as well as bronchoscopy with bronchoalveolar lavage (BAL) in patients with suspicion of pulmonary invasive aspergillosis (IA).

For diagnosis they recommend direct microscopy, preferably using optical brighteners, histopathology and culture as well as serum and BAL galactomannan measures as markers. PCR should be considered in conjunction with other diagnostic tests. Pathogen identification to species complex level is strongly recommended for all clinically relevant Aspergillus isolates; antifungal susceptibility testing should be performed in patients with invasive disease in regions with resistance found in contemporary surveillance programmes.

Isavuconazole and voriconazole are the preferred agents for first-line treatment of pulmonary IA, whereas liposomal amphotericin B is moderately supported. Combinations of antifungals as primary treatment options are not recommended. Therapeutic drug monitoring is strongly recommended for patients receiving posaconazole suspension or any form of voriconazole for IA treatment, and in refractory disease, where a personalized approach considering reversal of predisposing factors, switching drug class and surgical intervention is also strongly recommended.

Primary prophylaxis with posaconazole is strongly recommended in patients with acute myelogenous leukaemia or myelodysplastic syndrome receiving induction chemotherapy. Secondary prophylaxis is strongly recommended in high-risk patients. The experts strongly recommend treatment duration based on clinical improvement, degree of immunosuppression and response on imaging.

› Read more

Don’t miss the first two ECCMID 2018 keynote lectures on Saturday

On the 100th anniversary of the 1918 “Spanish” flu, infectious disease evolution specialists Colin A. Russell from the University of Amsterdam will hold a keynote lecture on influenza pandemics. His lecture will cover the history of influenza pandemics, the biological factors that lead to them, the challenges that remain, and the advances required to stop the next “big one”.

Then Nobel Prize winner Rolf M. Zinkernagel will talk about immunology taught by viruses. He will analyse the specificity and the antigen-dependence of protection, the characteristics of protective antibodies and T cells and their kinetics to explain general rules of immunity but also the success and failures of vaccines.

› Read more

CMI highlight: first WHO surveillance survey on AMR in leprosy

Antimicrobial resistance (AMR) in leprosy cannot be assessed as Mycobacterium leprae does not grow in vitro. A dedicated World Health Organization (WHO) network for the first time studied global data on AMR in leprosy. The researchers led by Emmanuelle Cambau from Paris collected data on molecular detection of resistance genes rpoB, folP1 and gyrA and conducted a prospective open survey of resistance to antileprosy drugs rifampicin, dapsone and ofloxacin in 19 endemic countries. Among 1,932 (1,143 relapse and 789 new) cases studied, 154 (8.0%) M. leprae strains were found with mutations conferring resistance showing 182 resistance traits (74 for rifampicin, 87 for dapsone, and 21 for ofloxacin). Twenty cases showed rifampicin and dapsone resistance, four showed ofloxacin and dapsone resistance, but no cases were resistant to rifampicin and ofloxacin. Rifampicin resistance was observed among relapses (58/1143, 5.1%) and new cases (16/789, 2.0 %) in twelve countries. India, Brazil and Colombia reported more than five rifampicin-resistant cases. Rifampicin resistance emerged stressing the expansion of surveillance programmes. The researcher also urged specialists to be vigilant about the global use of antimicrobial agents as ofloxacin resistance probably developed in relation to the general intake of antibiotics for other infections since it is not part of the multidrug combination to treat leprosy.

› Read more

ESGLI conference from 28 – 30 August 2018 in Lyon

ESGLI has published a newsletter with dates of upcoming activities as well as a list of research the study group is undertaking. One of the main activities is the 5th ESGLI meeting from 28 – 30 August 2018 in Lyon, France. The ESGLI 2018 conference will cover a wide range of topics related to Legionella and Legionnaires’ disease from basic microbial genetics and pathogenesis to applied aspects of detection, control and management. The goal of the meeting is to bring together researchers and professionals with more applied issues. The conference will present the latest scientific developments and knowledge about epidemiology and surveillance; clinical aspects and diagnosis; Host - Microbe interactions; Microbe - Environment interactions; outbreaks and case reports; genetics and genomics; prevention and control strategies.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Phone +41 61 5080 173
Visit us on LinkedIn Visit us on YouTube
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.